



Florida/Caribbean AIDS Education and Training Center

# HIV CareLink

A Newsletter for HIV/AIDS Primary Care Providers

## ABOUT US

The Florida/Caribbean AIDS Education and Training Center provides state-of-the-art HIV education, consultation, and resource materials to health care providers in Florida, Puerto Rico and the US Virgin Islands.

Major funding is provided by the US Public Health Service's Health Resources Services Administration (HRSA) DHHS-HAB Grant No. H4AHA00049 through the University of South Florida Center for HIV Education and Research, Michael Knox, PhD, Director.

### EDITORS

Jeffrey Beal, MD, AAHIVS  
(239) 839-4645  
aetcbear@embarqmail.com

Joanne J. Orrick, PharmD, AAHIVE  
(352) 273-7845  
orricj@ufl.edu

### PEDIATRIC EDITOR

Belinda Beauchamp, MD  
(787) 281-8501  
belinda.beauchamp@upr.edu

### MANAGING EDITOR

Kimberly Alfonso, MAcc  
(813) 974-4430  
alfonso@fmhi.usf.edu

Volume 10 - Issue 13

October 21, 2009

## H1N1 and HIV, Things You Should Know

### Jeffrey Beal, MD, AAHIVS

Clinical Director, Florida/Caribbean AIDS Education and Training Center  
Medical Director, Bureau of HIV/AIDS of the Florida Department of Health

### Gary Reavis, RN

Nurse Consultant, Bureau of HIV/AIDS of the Florida Department of Health

Included in this HIV CareLink is vaccine information from four approved manufacturers of the Novel H1N1 Vaccine including dosages and administrative criteria, and warnings and precautions. Antiviral medication dosing recommendations for treatment or chemoprophylaxis of H1N1 infection are outlined in table format. Safety of vaccine administration concurrent with other vaccines, and potential risks of H1N1 Monovalent Vaccine Live are discussed in the "Ask the Expert" column.

### VACCINE INFORMATION

There are four approved manufactures of the Novel H1N1 Vaccine. Each manufacturer has specific dosages and administration criteria.

#### (H1N1) 2009 MONOVALENT VACCINE LIVE, INTRANASAL BY MEDIMMUNE, LLC<sup>i</sup>

##### How supplied:

- Pre-filled single dose intranasal sprayer

##### Dosing/Administration:

Children (2-9 years)

- 2 doses (0.2 mL each, approximately 1 month apart, given as 0.1 mL in each nostril)

Children, adolescents and adults (10-49 years)

- A single dose (0.2 mL, given as 0.1 mL in each nostril)

##### Special handling instructions:

- Store 36°-46°F – Do not freeze

##### Adverse effects:

- Nose, runny or congested
- Sore throat in adults
- Fever >100° in children 2-6 years old

#### (H1N1) 2009 MONOVALENT VACCINE MANUFACTURED BY CSL LIMITED<sup>ii</sup>

##### How supplied:

- 0.5 mL single dose pre-filled syringe, no preservative
- 5mL multidose vial, contains thimerosal (each 0.5mL contains 24.5 mcg mercury)

##### Dosing/Administration:

Adults 18 years of age and older

- A single 0.5 mL intramuscular injection

##### Special handling instructions:

- Shake syringe and vial before drawing
- Store 36°-46°F – Do not freeze
- Destroy vial ≤ 28 days of first use
- Protect from light

##### Adverse effects:

- Injection-site tenderness, pain, redness, swelling
- Headache, malaise, muscle aches

For more information,  
please visit our website:

[www.FCAETC.org](http://www.FCAETC.org)

To request clinical consultation, please call the  
National Clinicians' Consultation Hotline:

**1-800-933-3413**

**(H1N1) 2009 MONOVALENT VACCINE NOVARTIS VACCINES AND DIAGNOSTICS LIMITED<sup>iii</sup>**

**How supplied:**

- 0.5 mL single dose pre-filled syringe, contains thimerosal (0.5 mL contains  $\leq 1$  mcg mercury)
- 5mL multidose vial, contains thimerosal (each 0.5mL contains 25 mcg mercury)

**Dosing/Administration:**

Children (4-9 years)

- Two 0.5 mL intramuscular injections approximately 1 month apart

Children (10-17 years)

- A single 0.5 mL intramuscular injection

Adults ( $\geq 18$  years)

- A single 0.5 mL intramuscular injection

**Special handling instructions:**

- Shake syringe and multi-dose vial before drawing
- Store 36°-46°F
- Use small syringe 0.5 mL for injection
- Do not freeze

**Adverse effects:**

- Rash
- Local reaction at injection site
- Influenza-like symptoms

**(H1N1) 2009 MONOVALENT VACCINE SANOFI PASTEUR 449/454 INFLUENZA A<sup>iv</sup>**

**How supplied:**

- 0.25 mL single dose pre-filled syringe, no preservative
- 0.5mL single dose pre-filled syringe, no preservative
- 0.5 mL single dose vial, no preservative
- 5 mL multidose vial contains thimerosal (each 0.5mL contains 25 mcg mercury)

**Dosing/Administration:**

Children (6-35 months)

- Two 0.25 mL intramuscular injections approximately 1 month apart

Children (36 months-9 years)

- Two 0.5 mL intramuscular injections approximately 1 month apart

**(H1N1) 2009 MONOVALENT VACCINE SANOFI PASTEUR 449/454 INFLUENZA A<sup>v</sup> (CONTINUE)**

10 years of age and older

- A single 0.5 mL dose, intramuscular injection

Adults

- A single 0.5 mL dose, intramuscular injection

**Special handling instructions:**

- Shake syringe and multi-dose vial before drawing
- Store 35°-46°F - Do not freeze

**Adverse effects:**

- Injection site soreness, pain, and swelling
- Malaise, headache, and myalgia

**WARNINGS AND PRECAUTIONS**

- All of the vaccines contain the following warnings and precautions:
  - Severe hypersensitivity to eggs, proteins, or a component of H1N1 vaccine
  - Prior life-threatening reaction to any influenza vaccine
  - If Guillain-Barré syndrome occurred within 6 weeks of a prior influenza vaccine, give only if the benefit is greater than the risks
  - Immuno compromised may have a decreased response
- Vaccine manufactured by CSL Limited was hypersensitive to chicken protein, neomycin, or polymyxin
- Live vaccine manufactured by MedImmune, LLC, was hypersensitive to gentamicin, gelatin, or arginine.
  - Do not administer to persons with asthma or to  $< 5\%$  with history of recurrent wheezing
  - Administer to immunocompromised patients, pregnant, and nursing women only if benefit is greater than the risks

**H1N1 SYMPTOMS**

The symptoms are any combination of the following: Fever, cough, sore throat, runny or stuffy nose, headache, body ache, chills, and fatigue. Additionally, symptoms may occur with or without diarrhea and vomiting.

The complete collection of previous issues of HIV CareLink are available online.

To view past issues, please visit the archives at:

[www.FCAETC.org/Newsletter](http://www.FCAETC.org/Newsletter)



### H1N1 CHEMOPROPHYLAXIS:

- Close contacts to H1N1
  - Caring for or living with or sharing eating or drinking materials with a confirmed, probable, or suspected case
  - Exposed within the interval of 1 day before source contact onset of symptoms until 24 hours after fever ends
  - Treat if exposed patient presents less than 48 hours since exposure
  - Zanamivir may be preferred (limited systemic absorption) for pregnant women unless history of respiratory problem where oseltamivir is a reasonable alternative
  - Treatment duration: 10 days after last known exposure

**Table 1**

Antiviral medication dosing recommendations for treatment or chemoprophylaxis of 2009 H1N1 infection.

(Table extracted from product information for Tamiflu® and Relenza®)  
<http://www.cdc.gov/h1n1flu/recommendations.htm>

Medication		Treatment (5 days)	Chemoprophylaxis (10 days)
<b>Oseltamivir</b>			
<i>Adults</i>			
		75-mg capsule twice per day	75-mg capsule once per day
<i>Children ≥ 12 months</i>			
Body Weight (kg)	Body Weight (lbs)		
≤15 kg	≤33lbs	30 mg twice daily	30 mg once per day
>15 kg to 23 kg	>33 lbs to 51 lbs	45 mg twice daily	45 mg once per day
>23 kg to 40 kg	>51 lbs to 88 lbs	60 mg twice daily	60 mg once per day
>40 kg	>88 lbs	75 mg twice daily	75 mg once per day
<b>Zanamivir</b>			
<i>Adults</i>			
		10 mg (two 5-mg inhalations) twice daily	10 mg (two 5-mg inhalations) once daily
<i>Children (≥7 years or older for treatment, ≥5 years for chemoprophylaxis)</i>			
		10 mg (two 5-mg inhalations) twice daily	10 mg (two 5-mg inhalations) once daily

### ASK THE EXPERT

Expert Opinion/Commentary for this issue provided by:

**Mobeen H. Rathore, MD, CPE, FIDSA, FACPE, FAAP**  
 Faculty, Florida/Caribbean AETC  
 Professor and Associate Chairman  
 Center of HIV/AIDS Research, Education and Service  
 University of Florida - Jacksonville, Florida

**Editor:** Is it safe to give H1N1 vaccine at the same time with the influenza vaccine or other vaccines such as Hepatitis A and B?

**Expert:** Any vaccine that is safe to give with seasonal flu vaccine is safe to give with H1N1 vaccine. To answer specifically, yes, it is safe to give with Hepatitis A and B vaccine.

**Editor:** It is said that H1N1 Monovalent Vaccine Live is not to be administered to immunocompromised individuals unless the benefit of doing so exceeds the potential risks<sup>vii</sup>.

**Expert:** The vaccine is live attenuated and we should always use this term rather than calling it live. It doesn't seem like a huge difference, but it is.

**Editor:** Should HIV-infected patients be around others who have received the live viral vaccine?

**Expert:** The following can be found on the CDC website: "People who are in contact with others with severely weakened immune systems when they are being cared for in a protective environment (for example, people with hematopoietic stem cell transplants), should not get LAIV (FluMist®). People who have contact with others with lesser degrees of immunosuppression (for example, people with diabetes, people with asthma taking corticosteroids, or people infected with HIV) can get LAIV (FluMist®)."

<http://www.cdc.gov/FLU/about/qa/nasalspray.htm>

The complete collection of previous issues of HIV CareLink are available online.

To view past issues, please visit the archives at:

[www.FCAETC.org/Newsletter](http://www.FCAETC.org/Newsletter)

## What Adults with HIV Infection Should Know About the Novel H1N1 Flu Virus?

Question and answer site from the CDC

[http://www.cdc.gov/h1n1flu/hiv\\_flu.htm](http://www.cdc.gov/h1n1flu/hiv_flu.htm)

### Useful Links for Healthcare Providers

H1N1 Clinicians Questions and Answers

[http://www.cdc.gov/h1n1flu/vaccination/clinicians\\_qa.htm](http://www.cdc.gov/h1n1flu/vaccination/clinicians_qa.htm)

Vaccine Information Statement (VIS) for Inactivated 2009 H1N1 Influenza Vaccine

<http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-inact-h1n1.pdf>

VIS for Live, Intranasal 2009 H1N1 Influenza Vaccine

<http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-laiv-h1n1.pdf>

State/Jurisdiction Contact Information for Healthcare

Providers Interested in Providing H1N1 Vaccine

<http://www.cdc.gov/h1n1flu/vaccination/statecontacts.htm>

2009 H1N1 Influenza Vaccine and Pregnant Women:

Information for Providers

[http://www.cdc.gov/h1n1flu/vaccination/providers\\_qa.htm](http://www.cdc.gov/h1n1flu/vaccination/providers_qa.htm)

CMS Billing for the Administration of the Influenza A (H1N1)

Virus Vaccine

<http://www.cms.hhs.gov/MLNMArticles/downloads/se0920.pdf>

### The Vaccine Adverse Event Reporting System (VAERS)

<http://www.vaers.hhs.gov/>

### References

- <sup>i</sup> "Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal", MedImmune, LLC, 10 September 2009, product insert.
  - <sup>ii</sup> "Influenza A (H1N1) 2009 Monovalent Vaccine", CSL Limited, 2009, September 2009, product insert.
  - <sup>iii</sup> "Influenza A (H1N1) 2009 Monovalent Vaccine", Novartis Vaccines and Diagnostics Limited, September 2009, product insert.
  - <sup>iv</sup> "Influenza A (H1N1) 2009 Monovalent Vaccine", Sanofi Pasteur 449/454 Influenza A, 10 September 2009\_v0.3, product insert.
  - <sup>v</sup> "Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal", MedImmune, LLC, 10 September 2009, product insert.
  - <sup>vi</sup> MedImmune, LLC, 10 September 2009, p. 10, product insert.
  - <sup>vii</sup> MedImmune, LLC, 10 September 2009, p. 21, product insert.
- Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season.
- <sup>v</sup> "Influenza A (H1N1) 2009 Monovalent Vaccine", Sanofi Pasteur 449/454 Influenza A, 10 September 2009\_v0.3, product insert.
  - <sup>v</sup> "Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal", MedImmune, LLC, 10 September 2009, product insert.
  - <sup>vi</sup> MedImmune, LLC, 10 September 2009, p. 10, product insert.
  - <sup>vii</sup> MedImmune, LLC, 10 September 2009, p. 21, product insert.
- Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season.

*Save the Date* May 14-15, 2010

**Florida/Caribbean AIDS Education and Training Center (AETC)**  
19<sup>th</sup> Annual HIV CONFERENCE

CHOOSE FROM FIVE HIV/AIDS CONCURRENT CLINICAL TRACKS:  
Fundamentals • Advanced • Nursing • Pediatrics • En Español

ROSEN SHINGLE CREEK  
Orlando

We're Moving Here! ↗

[www.FCAETC.org/Conference](http://www.FCAETC.org/Conference)

The complete collection of previous issues of HIV CareLink are available online.

To view past issues, please visit the archives at:

[www.FCAETC.org/Newsletter](http://www.FCAETC.org/Newsletter)